| Oct 17 |
Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain
|
| Oct 16 |
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
|
| Sep 30 |
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
|
| Sep 18 |
TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS)
|
| Sep 17 |
Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
|
| Sep 14 |
Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock
|
| Aug 30 |
Merus NV (MRUS): Top ADR Stock According to Hedge Funds
|
| Aug 14 |
Merus: Great European Oncology Developer, But Properly Valued
|
| Aug 14 |
Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks
|
| Aug 8 |
We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
|
